Home » News » Clinical Intelligence » Amgen and UCB report positive results for osteoporosis study

Amgen and UCB report positive results for osteoporosis study

Tuesday, April 26, 2011

California-based Amgen and Belgium-based UCB reported positive results from their phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). The 12-month phase 2 study is a multi-center, international, randomized, placebo-controlled and parallel-group study.

This phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at month 12 for the AMG 785/CDP7851 active arms versus the placebo arm. In addition, AMG 785/CDP7851 compared positively with the two active comparators, teriparatide and alendronate.

Adverse events were generally balanced between groups. Consistent with previous studies, injection site reactions were reported more frequently in those patients receiving AMG 785/CDP7851.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!